NCT00576251|CompletedPhase 3Results
Loading search results
Sponsor study identifier
interventional
221
1 country
1
Study Start
October 2007
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
February 2008
Actual (reported)Study Completion
March 2008
Date type not reportedThis date has not been verified as actual or estimated.
The purpose of this study is to describe the differences in efficacy between TOBRADEX Ophthalmic Suspension and Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension in the treatment of ocular inflammation and infection associated with blepharaconjunctivitis
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2008
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 2007
Date type not reportedThis date has not been verified as actual or estimated.
December 17, 2007
Actual (reported)December 19, 2007
Actual (reported)February 2008
Actual (reported)March 2008
Date type not reportedThis date has not been verified as actual or estimated.
January 14, 2010
Actual (reported)Percent of Patients Who Display Microbiological Success (Eradication of Baseline Pathogens at Day 4)
Microbiological success was declared if the pre-therapy pathogens were eradicated at the Exit Visit; conversely, microbiological failure was declared if pre-therapy pathogens persisted at the exit visit. The microbiological outcomes were calculated based on an algorithm that assessed whether pre-therapy pathogens were eradicated or persisted as demonstrated by comparative characterization of recovered bacteria.
Day 4 - Test Of Cure (TOC) compared to Day 0
Tobramycin 0.3%/Dexamethasone 0.05% 1 drop 4 times daily in both eyes
TOBRADEX 1 drop 4 times daily in both eyes
Tobramycin 0.3%/Dexamethasone 0.05% 1 drop in both eyes 4 times daily for at least 3 days
TOBRADEX 1 drop in both eyes 4 times daily for at least 3 days
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Grouped treatment entry
Tobramycin 0.3%/Dexamethasone 0.05%
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry recordHouston
Houston, Texas, 77090, United States
Michael Brubaker, BSN MPH
Alcon Research
221 participants (actual enrollment reported by the registry).
First Submitted
December 17, 2007
First Posted
December 19, 2007
Study Start
October 2007
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to confirm eligibility.
Primary Completion
February 2008
Actual (reported)Study Completion
March 2008
Date type not reportedThis date has not been verified as actual or estimated.
Last Updated
March 2, 2010
Results First Posted
January 14, 2010
Record last verified: 2010-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: